83 related articles for article (PubMed ID: 22033178)
1. Targeting RSK2 in myeloid leukemia: right for FLT3 but wrong for BCR-ABL.
Lee BH; Kang S
Cell Cycle; 2011 Nov; 10(21):3611-2. PubMed ID: 22033178
[No Abstract] [Full Text] [Related]
2. p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.
Elf S; Blevins D; Jin L; Chung TW; Williams IR; Lee BH; Lin JX; Leonard WJ; Taunton J; Khoury HJ; Kang S
Blood; 2011 Jun; 117(25):6885-94. PubMed ID: 21527514
[TBL] [Abstract][Full Text] [Related]
3. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Sattler M; Scheijen B; Weisberg E; Griffin JD
Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
[TBL] [Abstract][Full Text] [Related]
4. MSK1 activation in acute myeloid leukemia cells with FLT3 mutations.
Odgerel T; Kikuchi J; Wada T; Shimizu R; Kano Y; Furukawa Y
Leukemia; 2010 May; 24(5):1087-90. PubMed ID: 20357825
[No Abstract] [Full Text] [Related]
5. Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL.
Mali RS; Ramdas B; Ma P; Shi J; Munugalavadla V; Sims E; Wei L; Vemula S; Nabinger SC; Goodwin CB; Chan RJ; Traina F; Visconte V; Tiu RV; Lewis TA; Stern AM; Wen Q; Crispino JD; Boswell HS; Kapur R
Cancer Cell; 2011 Sep; 20(3):357-69. PubMed ID: 21907926
[TBL] [Abstract][Full Text] [Related]
6. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
7. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
[TBL] [Abstract][Full Text] [Related]
8. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.
Alvarez-Calderon F; Gregory MA; Pham-Danis C; DeRyckere D; Stevens BM; Zaberezhnyy V; Hill AA; Gemta L; Kumar A; Kumar V; Wempe MF; Pollyea DA; Jordan CT; Serkova NJ; Graham DK; DeGregori J
Clin Cancer Res; 2015 Mar; 21(6):1360-72. PubMed ID: 25547679
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.
Neuendorff NR; Burmeister T; Dörken B; Westermann J
Ann Hematol; 2016 Aug; 95(8):1211-21. PubMed ID: 27297971
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells.
Mihailovic T; Marx M; Auer A; Van Lint J; Schmid M; Weber C; Seufferlein T
Cancer Res; 2004 Dec; 64(24):8939-44. PubMed ID: 15604256
[TBL] [Abstract][Full Text] [Related]
12. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H
Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983
[TBL] [Abstract][Full Text] [Related]
13. KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts.
Andersson BS; Collins VP; Kurzrock R; Larkin DW; Childs C; Ost A; Cork A; Trujillo JM; Freireich EJ; Siciliano MJ
Leukemia; 1995 Dec; 9(12):2100-8. PubMed ID: 8609723
[TBL] [Abstract][Full Text] [Related]
14. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
Chougule RA; Kazi JU; Rönnstrand L
Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
[TBL] [Abstract][Full Text] [Related]
15. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.
Klejman A; Schreiner SJ; Nieborowska-Skorska M; Slupianek A; Wilson M; Smithgall TE; Skorski T
EMBO J; 2002 Nov; 21(21):5766-74. PubMed ID: 12411494
[TBL] [Abstract][Full Text] [Related]
16. Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
Sindt A; Deau B; Brahim W; Staal A; Visanica S; Villarese P; Rault JP; Macintyre E; Delabesse E
Genes Chromosomes Cancer; 2006 Jun; 45(6):575-82. PubMed ID: 16518848
[TBL] [Abstract][Full Text] [Related]
17. A case of acute erythroleukemia with concurrence of BCR-ABL and FLT3-TKD (D835E) mutation.
Cheng W; Yang X; Ping N; Chen S; Sun A
Leuk Lymphoma; 2015; 56(8):2463-4. PubMed ID: 25547655
[No Abstract] [Full Text] [Related]
18. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
19. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract][Full Text] [Related]
20. The involvement of Bcr in leukemias with the Philadelphia chromosome.
Arlinghaus RB
Crit Rev Oncog; 1998; 9(1):1-18. PubMed ID: 9754444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
